作者：Rodney P. Rocconi, J. Michael Straughn, Jr., Charles A. Leath, III, Larry C. Kilgore, Warner K. Huh
Mack N. Barnes, III, Edward E. Partridge, Ronald D. Alvarez
【关键词】 Ovarian,cancer,•,Chemotherapy,•,Consolidation,therapy,•,Doxorubicin
ABSTRACT
Objective. To assess the feasibility of using pegylated liposomal doxorubicin (PLD) as a consolidation therapy in patients with advanced ovarian cancer who have attained a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy.
Methods. Patients diagnosed with suboptimally debulked stage IIIC/IV epithelial ovarian cancer who attained a clinically defined complete response at the completion of platinum/paclitaxel-based chemotherapy were eligible for this protocol. Patients were treated with PLD at a dose of 40 mg/m2 every 28 days for four cycles. A survival analysis was calculated using the Kaplan-Meier method.
Results. Of the 30 patients enrolled, 29 were evaluable. Twenty-three patients (79%) completed all four cycles of consolidation therapy. Palmar-plantar erythrodysesthesia was the most common toxicity. Six patients remained clinically without evidence of disease with a median follow-up of 35 months from the completion of primary chemotherapy. The median progression-free interval was 15 months, and……
<<<<<全文未完，本文约87个中文字，未计算英文字母、数字>>>>>
